Allianz Asset Management
AIMT

Allianz Asset Management’s Aimmune Therapeutics AIMT Stock Holding History

Allianz Asset Management’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-669,560
Closed -$23.1M – 2012
2020
Q3 		$23.1M Buy
+669,560
New +$14.3M 0.03% 523

Allianz Asset Management's AIMT Position: Q4 2020 in Review

Allianz Asset Management sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 669,560 shares — an estimated $23.1M sold.

Allianz Asset Management first reported a position in AIMT in Q3 2020 and held it in 1 quarter. The position peaked at $23.1M in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

  • Allianz Asset Management reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Allianz Asset Management sold 669,560 Aimmune Therapeutics shares in Q4 2020, an estimated $23.1M.
  • Allianz Asset Management first reported a position in Aimmune Therapeutics in Q3 2020 and held it in 1 quarter.
  • Allianz Asset Management's Aimmune Therapeutics position peaked at $23.1M in Q3 2020.
  • 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Allianz Asset Management's 13F filing for Q4 2020, filed 16 Feb 2021.